DOCSLIB.ORG

Progestogen and Progesterone Regimens In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Progestogen and Progesterone Regimens In Progestogen and Patient Advice & Liaison Progesterone regimens in HRT Service (PALS) Progestogens or progesterone should only If you have concerns or wish to give feedback about be taken following the regimen advised by services, your care or treatment, you can contact the your specialist. PALS office on the Ground Floor of the hospital just behind the main reception. Continuous combined HRT regimens: Alternatively, you can send us your comments or • Norethisterone 5mg, every day suggestions on one of our comment cards, available • Utrogestan 100mg every night at the PALS office, or on a feedback form on our website www.chelwest.nhs.uk/pals. Progestogen Sequential combined HRT regimens: We value your opinion and invite you to provide us • Norethisterone 5mg twice daily, for 12- with feedback. and 14 days every month • Utrogestan 200mg (2x100mg capsules) T: 020 3315 6727 at night for 12-14 days every month E: [email protected] Progesterone Further advice and support Regimens in www.the-bms.org (British Menopause Society) HRT www.menopausematters.co.uk www.womens-health-concern.org www.chelwest.nhs.uk/services/womens- health-services Chelsea and Westminster Hospital Information for patients NHS Foundation Trust 369 Fulham Road London SW10 9NH T: 020 3315 8000 W: www.chelwest.nhs.uk January 2016 If you need to re-schedule your appointment, please ring the appointments office on 020 3315 6666. Progestogens and Progesterone When is a continuous progestogen or Deviation from the recommended licensed progesterone used in HRT? regimen may significantly increase the short-term Hormone replacement therapy (HRT) may be risk of irregular bleeding or the long-term risk of If periods have stopped for more than one year, then recommended for women whose periods have stopped developing endometrial cancer. Therefore, a progestogen or progesterone is taken every day and the ovaries are no longer producing estrogen. reducing the dose or number of days that the with estrogen. With this regimen there will be no Women who have not had a hysterectomy will have both progestogen or progesterone is taken should only bleeding. Common prescriptions are: estrogen and a progestogen or progesterone prescribed be taken under specialist guidance. (combined HRT). • Norethisterone 5mg, every day • Utrogestan 100mg capsule, every night Is an ultrasound needed? When is combined hormone therapy An ultrasound may be recommended if there is a recommended? When is a cyclical progestogen or history of new or irregular bleeding. If you progesterone used in HRT? experience new or irregular bleeding, Both estrogen with a progestogen or progesterone are please contact your GP in the first instance prescribed for short-term symptom relief and long-term If periods have not stopped for one year then there is for advice. health protection. a risk of further menstrual bleeds occurring. To avoid the risk of irregular bleeding on HRT a progestogen If you are on a continuous HRT regimen or post- or progesterone is taken for 12-14 days each month menopausal, you should be referred directly to What is the difference between and an artificially induced bleed will follow the local gynaecology rapid access service and a progestogens and progesterone? discontinuation. Common prescriptions are: hysteroscopy may be necessary. Progestogens are synthetic molecules that mimic the • Norethisterone 5mg twice daily, for 12-14 If you are on a cyclical HRT regimen and your action of the ovarian progesterone hormone. There are days every 28 days normal bleeding pattern has changed, then an several different progestogens all with slightly different • Utrogestan 2x100mg capsules at night, for ultrasound may be recommended. properties. 12-14 days every 28 days Progesterone is produced by the ovary. Its role is to Is contraception needed with HRT? maintain a pregnancy, protect the lining of the womb Why is a progestogen or progesterone (endometrium) and control bleeding. important? HRT is not a contraceptive. If you are not postmenopausal, then you may be at risk of In the menstrual cycle, ovarian progesterone protects What is natural or bio-identical pregnancy. The only licensed contraceptive for the endometrium and induces a monthly bleed to use with HRT is the Mirena intrauterine system progesterone? reduce the risk of developing abnormal cancerous containing levonorgestrel. For any other Natural or bio-identical are interchangeable terms that cells. Combined HRT mimics this protective action combined HRT combination, the contraceptive refer to a natural form of progesterone that is identical only if the progestogen or progesterone is taken at options include: to ovarian progesterone (also called body-identical). Bio- the correct dose and for the recommended number of days. • Barrier contraception identical natural progesterone is synthesised from yams. • Copper coil It is only licensed for HRT use as an oral micronised What is progesterone intolerance? • Progesterone only pill progesterone capsule. Other licensed progesterone products may be used with HRT, under the supervision Some women develop side-effects to progestogens or of a specialist. progesterone. This reaction may be limited to a single Sublingual (under the tongue) or transdermal progestogen or progesterone, or from all types. progesterone is not licensed or regulated, therefore is Symptoms are similar to premenstrual syndrome and not recommended for use with licensed HRT. may require a modified combined HRT regimen. .
Load more

Recommended publications
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • The Progestogen Only Pill
    The Progestogen Only Pill Mini-pill or POP A service provided by page 2 of 8 How does the progestogen only pill (POP) work? The progestogen only pill mainly works by thickening the mucus you produce from your cervix. This makes it more difficult for sperm to get to the egg. It can also sometimes stop your ovaries from producing an egg (ovulation). How effective is the pill? The effectiveness of the pill depends on the woman taking it. At best it is over 98% effective (when no pills are missed). However failure rates can be much higher (9-15%) if women do not remember to take their pill properly. Missed pills can lead to pregnancy. Advantages of the POP • It doesn’t interfere with sex. • You can use it whilst you are breastfeeding. • It is useful if you cannot take oestrogen (the hormone contained in the combined oral contraceptive) • Can be used at any age even if you smoke and are over 35 years of age. • It may help with premenstrual symptoms and painful periods. page 3 of 8 Disadvantages of the POP • You have to remember to take your pill at the same time every day. • Your periods may become irregular or even stop altogether on the POP, this is not dangerous but if you miss a period you need to check that you are not pregnant by coming to clinic for a pregnancy test. • You may get some temporary side effects, such as spotty skin, breast tenderness and mood changes, though these should stop within a few months.
    [Show full text]
  • Progestin-Only Systemic Hormone Therapy for Menopausal Hot Flashes
    EDITORIAL Progestin-only systemic hormone therapy for menopausal hot flashes Clinicians treating postmenopausal hot flashes often recommend “systemic estrogen treatment.” However, progestin-only therapy also can effectively treat hot flashes and is an option for women with a contraindication to estrogen therapy. Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School he field of menopause medi- women. In one study, 133 postmeno- in postmenopausal women with cine is dominated by studies pausal women with an average age an American Heart Association risk T documenting the effective- of 55 years and approximately 3 years score greater than 10% over 10 years.3 ness of systemic estrogen or estro- from their last menstrual period were Additional contraindications to sys- gen-progestin hormone therapy for randomly assigned to 12 weeks of temic estrogen include women with the treatment of hot flashes caused treatment with placebo or micronized cardiac disease who have a throm- by hypoestrogenism. The effective- progesterone 300 mg daily taken at bophilia, such as the Factor V Leiden ness of progestin-only systemic bedtime.1 Mean serum progesterone mutation.4 hormone therapy for the treatment levels were 0.28 ng/mL (0.89 nM) and For women who are at high risk of hot flashes is much less studied 27 ng/mL (86 nM) in the women taking for estrogen-induced cardiovascu- and seldom is utilized in clinical placebo and micronized progesterone, lar events, micronized progesterone practice.
    [Show full text]
  • Informed Consent for Feminizing Hormone Therapy
    Informed Consent for Feminizing Hormone Therapy For _________________________ Date of Birth: _____________ Name Used: ____________________ Patient Name as listed in chart Name if different from chart This form will assist you (and your guardian) to think through the expected effects of hormone therapy including possible unwanted side effects. You are encouraged to talk about this treatment with your medical provider and decide if hormone therapy is right for you (your child). By signing this form, you are stating that you have discussed the effects and risks of this medication with your medical provider or a member of the medical team and that you understand and accept these effects and possible risks. You (and your guardian) may ask questions and talk about any concerns you have related to this treatment at any time in this process. Estrogen (usually estradiol) is used to feminize the body (make it look more traditionally female). This medical treatment will reduce some male features and increase some female features of the body. Androgen (testosterone) blockers further decrease the amount of and/or block the effect of testosterone and masculinization of the body. Your medical provider will help decide which form and the amount of estrogen (shots, pills, gels, patches) and androgen blockers (pills, gels, shots, implanted) that are best for you based on your personal needs and any medical or mental health conditions you might have. Each person’s body responds to estrogen differently and it is hard to promise or predict with certainty how each person may respond to treatment. Your medical provider will talk with you throughout the treatment and will help you achieve the best results safely.
    [Show full text]
  • A Guide to Feminizing Hormones – Estrogen
    1 | Feminizing Hormones ​ ​ A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, ​ when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex ​ organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), ​ dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone ​ • Progestin: progesterone ​ Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • WHO Statement on Progestogen-Only Implants
    WHO statement on Progestogen-only implants Key facts Progestogen-only implants consist of hormone-filled capsules or rods that are inserted under the skin in a woman’s upper arm The purpose of this Statement is to reiterate and Life-Saving Commodities for Women and Children clarify the existing (current) WHO position based on endorsed contraceptive implants as one of its 13 Life- published guidance that is still valid. WHO monitors Saving Commodities. the evidence in this field closely and will update Primary mechanisms of action of the implants include its guidance as and when new evidence becomes thickening cervical mucus (making it difficult for available. sperm to penetrate) and preventing ovulation in KEY FACTS ABOUT PROGESTOGEN-ONLY IMPLANTS about half of menstrual cycles. Long-acting reversible contraceptives, including USE OF PROGESTOGEN-ONLY IMPLANTS BY intrauterine devices and implants are the most WOMEN LIVING WITH HIV effective methods of reversible contraception. These There have been concerns from recent publications methods have multiple advantages over other regarding the effectiveness of progestogen-only reversible methods. Most importantly, once in place, implants among women living with HIV and on they do not require daily or monthly dosing and their some antiretroviral drugs.1 However, compared with duration of contraceptive action ranges from 3 to 5 other hormonal methods, no significant differences years. in pregnancy rates have been observed with Progestogen-only implants consist of hormone-filled progestogen-only implants.2 capsules or rods that are inserted under the skin of a woman’s upper arm. Current systems consist of one or two rods.
    [Show full text]
  • Exposure to Female Hormone Drugs During Pregnancy
    British Journal of Cancer (1999) 80(7), 1092–1097 © 1999 Cancer Research Campaign Article no. bjoc.1998.0469 Exposure to female hormone drugs during pregnancy: effect on malformations and cancer E Hemminki, M Gissler and H Toukomaa National Research and Development Centre for Welfare and Health, Health Services Research Unit, PO Box 220, 00531 Helsinki, Finland Summary This study aimed to investigate whether the use of female sex hormone drugs during pregnancy is a risk factor for subsequent breast and other oestrogen-dependent cancers among mothers and their children and for genital malformations in the children. A retrospective cohort of 2052 hormone-drug exposed mothers, 2038 control mothers and their 4130 infants was collected from maternity centres in Helsinki from 1954 to 1963. Cancer cases were searched for in national registers through record linkage. Exposures were examined by the type of the drug (oestrogen, progestin only) and by timing (early in pregnancy, only late in pregnancy). There were no statistically significant differences between the groups with regard to mothers’ cancer, either in total or in specified hormone-dependent cancers. The total number of malformations recorded, as well as malformations of the genitals in male infants, were higher among exposed children. The number of cancers among the offspring was small and none of the differences between groups were statistically significant. The study supports the hypothesis that oestrogen or progestin drug therapy during pregnancy causes malformations among children who were exposed in utero but does not support the hypothesis that it causes cancer later in life in the mother; the power to study cancers in offspring, however, was very low.
    [Show full text]
  • SLINDA® (DROSPIRENONE 4 Mg) TABLETS
    SLINDA® (DROSPIRENONE 4 mg) TABLETS AUSTRALIAN PRODUCT INFORMATION AUSTRALIAN PRODUCT 4.2 Dose And Method Of INFORMATION Administration SLINDA® (DROSPIRENONE) TABLETS Dose How to take SLINDA 1. NAME OF THE MEDICINE One tablet is to be taken daily for 28 Drospirenone consecutive days; one white active tablet daily during the first 24 days and one green inactive tablet 2. QUALITATIVE daily during the 4 following days. Tablets must be taken every day, at about AND QUANTITATIVE the same time of the day, so that the COMPOSITION interval between two tablets is always 24 hours. Tablets should be taken in White active film-coated tablets: the order shown on the blister. Stickers Each tablet contains 4 mg of marked with the 7 days of the week are drospirenone. provided. The patient should choose the sticker that starts with the day they Green placebo film-coated tablets: begin taking the tablets and stick it on The tablet does not contain active the blister. substances. The first tablet of the treatment should Excipient(s) with known effect: be taken on the first day of menstrual Each white active film-coated tablet bleeding. Thereafter tablet taking contains 17.5 mg of lactose. is continuous. A subsequent pack is started immediately after finishing the Each green placebo film-coated tablet previous pack, without a break in daily contains 55.5 mg of lactose monohydrate. tablet intake. For the full list of excipients, see section How to start SLINDA 6.1 List of Excipients. No preceding hormonal contraceptive use (in the past month) Tablet-taking has to start on day 1 of the 3.
    [Show full text]
  • Desogestrel-Only Pill (Cerazette)
    J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197593 on 1 July 2003. Downloaded from Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit A unit funded by the FFPRHC and supported by the University of Aberdeen and SPCERH to provide guidance on evidence-based practice New Product Review (April 2003) Desogestrel-only Pill (Cerazette) Journal of Family Planning and Reproductive Health Care 2003; 29(3): 162–164 Evidence from a randomised trial has shown that a 75 mg (microgrammes) desogestrel pill inhibits ovulation in 97% of cycles. Thus, on theoretical grounds, we would expect the desogestrel pill to be more effective than existing progestogen- only pills (POPs). However, Pearl indices from clinical trials comparing it to a levonorgestrel POP were not significantly different. Therefore an evidence-based recommendation cannot be made that the desogestrel pill is different from other POPs in terms of efficacy, nor that it is similar to combined oral contraception (COC) in this respect. An evidence-based recommendation can be made that the desogestrel-only pill is similar to other POPs in terms of side effects and acceptability. The desogestrel-only pill is not recommended as an alternative to COC in routine practice, but provides a useful alternative for women who require oestrogen-free contraception. In clinical trials: l Ovulation was inhibited in 97% of cycles at 7 and 12 months after initiation. l The Pearl index was 0.41 per 100 woman-years, which was not significantly different from a levonorgestrel-only pill. However, the trial providing these data was too small to detect a clinically important difference.
    [Show full text]
  • Menopausal Hormone Therapy
    GYNAECOLOGY ENDOCRINOLOGY Menopausal hormone therapy: where are we now? Menopausal hormone therapy (MHT) is an effective treatment for symptoms associated with menopause, such as hot flushes, night sweats, mood changes, sleep disturbances and changes in sexual function. While the evidence around MHT has changed over the years, there is now international consensus that the benefits of MHT are likely to outweigh the risks for most women aged < 60 years or within ten years of menopause, for whom menopausal symptoms are affecting their quality of life. KEY PRACTICE POINTS: Every woman’s experience of menopause is different, and Among the oestrogen and progestogen formulations perceptions of menopause vary across cultures. Most available, transdermal oestrogen (funded) and micronised women will experience some menopause symptoms, progesterone (not funded) are associated with the lowest however, only some will seek treatment. risk of adverse effects Menopausal hormone therapy (MHT) is likely to offer overall There is no specific recommended duration for MHT. The benefit to women with menopausal symptoms affecting decision to continue treatment should be reviewed on their quality of life if they are aged < 60 years or within ten an annual basis, taking into account any changes in the years of menopause patient’s risk factors, adverse effects and extent of benefit. Adverse outcomes associated with MHT include breast If women primarily seek assistance for urogenital symptoms cancer, stroke and venous thromboembolism (VTE). of menopause, vaginal products are recommended instead However, the risk of these outcomes depends on factors of MHT. This includes moisturisers, lubricants or a vaginal such as the age or time since menopause when MHT oestrogen cream or pessary.
    [Show full text]
  • Dose Response Effect of Cyclical Medroxyprogesterone on Blood Pressure in Postmenopausal Women
    Journal of Human Hypertension (2001) 15, 313–321 2001 Nature Publishing Group All rights reserved 0950-9240/01 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Dose response effect of cyclical medroxyprogesterone on blood pressure in postmenopausal women PJ Harvey1, D Molloy2, J Upton2 and LM Wing1 Departments of 1Clinical Pharmacology and 2Medicine, Flinders University of South Australia, Bedford Park, Adelaide, South Australia, Australia 5042 Objective: This study was designed to compare with mean values of weeks 3 and 4 of each phase used for placebo the dose-response effect of cyclical doses of analysis. Ambulatory BP was performed in the final the C21 progestogen, medroxyprogesterone acetate week of each phase. (MPA) on blood pressure (BP) when administered to Results: Compared with the placebo phase, end of normotensive postmenopausal women receiving a fixed phase clinic BP was unchanged by any of the proges- mid-range daily dose of conjugated equine oestrogen togen treatments. There was a dose-dependent (CEE). decrease in ambulatory daytime diastolic and mean Materials and methods: Twenty normotensive post- arterial BP with the progestogen treatments compared menopausal women (median age 53 years) participated with placebo (P Ͻ 0.05). in the study which used a double-blind crossover Conclusion: In a regimen of postmenopausal hormone design. There were four randomised treatment phases, replacement therapy with a fixed mid-range daily dose each of 4 weeks duration. The four blinded treatments of CEE combined with a cyclical regimen of a C21 pro- were MPA 2.5 mg, MPA 5 mg, MPA 10 mg and matching gestogen spanning the current clinical dose range, the placebo, taken for the last 14 days of each 28 day treat- progestogen has either no effect or a small dose-depen- ment cycle.
    [Show full text]